Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares ...

Viatris Inc reaffirmed its full-year revenue forecast on Monday and said it was on track to achieve about $500 million in annual sales from its newly launched products, sending its shares up ...

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow morning. Here’s what you need to know.

Viatris surpassed expectations in Q2 2023 with increased revenue and R&D spending. Click here to find out why VTRS stock is rated as a buy.

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS guidance.

Viatris (VTRS) stock rises in reaction to positive Phase 3 trial results and its better-than-expected Q1 2025 financials. Read more here.

Viatris, which is in the midst of a strategy shift intended to return the company to revenue growth, is acquiring two companies that together bring one commercialized product and five programs ...

Viatris Inc. research and ratings by Barron's. View VTRS revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Shares of Viatris Inc. VTRS slipped 3.52% to $8.77 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.07% to 5,659.91 and ...

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Viatris will spend as much as $335 million to settle opioid-related claims against the Canonsburg-based pharmaceutical company.